Kalpit Patel
Stock Analyst at B. Riley Securities
(0.87)
# 3,895
Out of 4,984 analysts
59
Total ratings
32.56%
Success rate
-11.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DERM Journey Medical | Maintains: Buy | $9 → $12 | $7.05 | +70.21% | 6 | Jul 30, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $48.12 | +24.69% | 5 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $6.92 | +102.31% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $17.51 | +111.31% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $34.22 | -29.87% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.27 | +175.59% | 4 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $9.44 | -4.66% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.80 | +108.33% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.15 | +508.70% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $11.62 | +244.23% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.16 | +158.62% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $18.62 | +7.41% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.04 | +886.84% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $14.75 | +144.07% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.00 | +4,400.00% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.13 | +1,492.92% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.80 | +177.78% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.24 | +602.25% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $11.96 | +527.09% | 2 | Sep 3, 2021 |
Journey Medical
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $7.05
Upside: +70.21%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $48.12
Upside: +24.69%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $6.92
Upside: +102.31%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $17.51
Upside: +111.31%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $34.22
Upside: -29.87%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.27
Upside: +175.59%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $9.44
Upside: -4.66%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.80
Upside: +108.33%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.15
Upside: +508.70%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $11.62
Upside: +244.23%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.16
Upside: +158.62%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $18.62
Upside: +7.41%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.04
Upside: +886.84%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $14.75
Upside: +144.07%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.00
Upside: +4,400.00%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.13
Upside: +1,492.92%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.80
Upside: +177.78%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $14.24
Upside: +602.25%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $11.96
Upside: +527.09%